Nitya Bakshi, MBBS, MS
she/her/hers
Associate Professor of PediatricsCards
About
Research
Overview
Medical Research Interests
Anemia, Sickle Cell; Chronic Pain; Integrative Medicine; Patient Reported Outcome Measures; Research Support, N.I.H., Extramural; Sickle Cell Trait; Support of Research
Publications
2025
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.
Kassim AA, Walters MC, Eapen M, Smith M, Logan BR, Solh M, McKinney C, Nieder M, Ross M, Kent M, Abusin GA, Mallhi K, Silva JG, Shaughnessy P, Kanter J, Haines H, Farah R, Khaled YA, Ritzau N, Mendizabal A, Abraham A, Bollard C, Cooke K, de la Fuente J, Hanna R, Horowitz MM, Jordan LC, Bakshi N, Krishnamurti L, Leifer E, Mahadeo KM, Shenoy S, Jones RJ, DeBaun MR, Brodsky RA. Haploidentical Bone Marrow Transplantation for Sickle Cell Disease. NEJM Evid 2025, 4: EVIDoa2400192. PMID: 39998298, DOI: 10.1056/EVIDoa2400192.Peer-Reviewed Original Research
2024
Hematopoietic Cell Transplant compared with Standard Care in Adolescents and Young Adults with Sickle Cell Disease
Walters M, Eapen M, Liu Y, El Rassi F, Waller E, Levine J, Strouse J, Antin J, Parikh S, Bakshi N, Dampier C, Jaroscak J, Bergmann S, Wong T, Kota V, Pace B, Lekakis L, Lulla P, Nickel R, Kasow K, Popat U, Smith W, Yu L, DiFronzo N, Geller N, Kamani N, Klings E, Hassell K, Mendizabal A, Sullivan K, Neuberg D, Krishnamurti L. Hematopoietic Cell Transplant compared with Standard Care in Adolescents and Young Adults with Sickle Cell Disease. Blood Advances 2024 PMID: 39471440, DOI: 10.1182/bloodadvances.2024013926.Peer-Reviewed Original ResearchHematopoietic cell transplantationVaso-occlusive painStandard of careSickle cell diseaseCell transplantationCell diseaseSCD-related eventsHLA-matched siblingTransplant-related mortalityPeriod of follow-upSurvival 2 yearsIntent-to-treat principleComparison of survivalDisease-modifying therapiesDisease-related mortalityUnrelated donorPrimary endpointCurative potentialTreatment armsDonor searchFollow-upCompare outcomesEligibility confirmationFunctional outcomesSecondary outcomesLong‐term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis
Arnold S, Bakshi N, Ross D, Smith C, Sinha C, Veludhandi A, Dutreuil V, Bai S, Meacham L, Guilcher G, Bhatia M, Abraham A, Kasow K, Haight A, Rassi F, Stenger E, Lipscomb J, Krishnamurti L. Long‐term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis. American Journal Of Hematology 2024, 99: 2037-2040. PMID: 39105410, DOI: 10.1002/ajh.27436.Peer-Reviewed Original ResearchImpact of arginine therapy on kyotorphin in children with sickle cell disease and vaso-occlusive pain
Korman R, Hatabah D, Brown L, Harris F, Wilkinson H, Rees C, Bakshi N, Archer D, Dampier C, Morris C. Impact of arginine therapy on kyotorphin in children with sickle cell disease and vaso-occlusive pain. Blood Advances 2024, 8: 3267-3271. PMID: 38527291, PMCID: PMC11226964, DOI: 10.1182/bloodadvances.2023012209.Peer-Reviewed Original ResearchHigh-impact chronic pain in sickle cell disease: insights from the Pain in Sickle Cell Epidemiology Study (PiSCES)
Jagtiani A, Chou E, Gillespie S, Liu K, Krishnamurti L, McClish D, Smith W, Bakshi N. High-impact chronic pain in sickle cell disease: insights from the Pain in Sickle Cell Epidemiology Study (PiSCES). Pain 2024, 165: 2364-2369. PMID: 38787626, PMCID: PMC11404329, DOI: 10.1097/j.pain.0000000000003262.Peer-Reviewed Original ResearchHigh-impact chronic painSickle Cell Epidemiology StudyChronic painProportion of daysUS National Pain StrategySickle cell diseaseNational Pain StrategySelf-care activitiesEpidemiological studiesHigher levels of stressMean pain intensityCohort of individualsPain interferenceLevels of stressPhysical functionHealth outcomesHealthcare utilizationPhysical healthPain strategiesPain burdenPain intensityPain diaryCell diseaseDiary daysAffected subgroups
2023
A cognitive–behavioral digital health intervention for sickle cell disease pain in adolescents: a randomized, controlled, multicenter trial
Palermo T, Lalloo C, Zhou C, Dampier C, Zempsky W, Badawy S, Bakshi N, Ko Y, Nishat F, Stinson J. A cognitive–behavioral digital health intervention for sickle cell disease pain in adolescents: a randomized, controlled, multicenter trial. Pain 2023, 165: 164-176. PMID: 37733479, PMCID: PMC10723646, DOI: 10.1097/j.pain.0000000000003009.Peer-Reviewed Original ResearchConceptsSickle cell diseaseEducation controlSickle Cell Disease PainEvidence-based cognitive behavioral therapySickle cell painAverage pain intensitySignificant healthcare costsCognitive behavioral therapy programCognitive behavioral therapyDigital health interventionsPain daysSCD clinicSecondary outcomesCommon complicationDisease painMulticenter trialPain intensityPain interferenceChronic painPain interventionsEffective implementation strategiesGlobal ImpressionCell diseasePsychosocial distressPainPatient-reported outcomes in children with sickle cell disease at presentation for an acute pain episode
Bakshi N, Liu Z, Gillespie S, Keesari R, Leake D, Khemani K, Kumari P, Rees C, Dampier C, Morris C. Patient-reported outcomes in children with sickle cell disease at presentation for an acute pain episode. Blood Advances 2023, 7: 5103-5107. PMID: 36322873, PMCID: PMC10477437, DOI: 10.1182/bloodadvances.2021006794.Peer-Reviewed Original ResearchSickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial
Rees C, Brousseau D, Cohen D, Villella A, Dampier C, Brown K, Campbell A, Chumpitazi C, Airewele G, Chang T, Denton C, Ellison A, Thompson A, Ahmad F, Bakshi N, Coleman K, Leibovich S, Leake D, Hatabah D, Wilkinson H, Robinson M, Casper T, Vichinsky E, Morris C. Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial. Trials 2023, 24: 538. PMID: 37587492, PMCID: PMC10433602, DOI: 10.1186/s13063-023-07538-z.Peer-Reviewed Original ResearchConceptsPediatric Emergency Care Applied Research NetworkSickle cell disease treatmentVaso-occlusive episodesSickle cell diseaseSTART trialArginine therapyIntravenous arginineLoading doseNormal saline three timesYoung adultsBlood Institute guidelinesParental opioid usePlacebo loading doseSubstantial illness burdenDisease-modifying therapiesPatient-reported outcomesDisease treatmentPhase 3Emergency medicine providersSaline three timesMulticenter research networkResearch NetworkIntravenous opioidsLast doseStudy drugSex and frequency of pain episodes are associated with acute pain trajectories in adolescents with sickle cell disease
Astles R, Liu Z, Gillespie S, Lai K, Maillis A, Morris C, Lane P, Krishnamurti L, Bakshi N. Sex and frequency of pain episodes are associated with acute pain trajectories in adolescents with sickle cell disease. PAIN Reports 2023, 8: e1084. PMID: 37559677, PMCID: PMC10409410, DOI: 10.1097/pr9.0000000000001084.Peer-Reviewed Original ResearchHigher health care utilizationHealth care utilizationSickle cell diseaseAcute pain trajectoriesPain intensity scoresEmergency departmentPain trajectoriesPain episodesCell diseaseHigher mean pain intensity scoreIntensity scoresMean pain intensity scoreAcute pain episodesFrequency of painAdolescent female patientsFuture prospective studiesElectronic health recordsIntranasal opioidsPain frequencyAcute painPain intensityRetrospective reviewCare utilizationFemale patientsProspective studyParental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation
Sinha C, Meacham L, Bakshi N, Ross D, Krishnamurti L. Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation. Pediatric Blood & Cancer 2023, 70: e30276. PMID: 37051746, PMCID: PMC10544372, DOI: 10.1002/pbc.30276.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationRisk of infertilitySickle cell diseaseStem cell transplantationFertility preservationCell transplantationCell diseaseMajor long-term complicationPrimary caregiversIdentical related donorsDisease-free survivalFertility preservation optionsFertility preservation proceduresLong-term complicationsHuman leukocyte antigenConditioning regimenHost diseaseRelated donorsLeukocyte antigenPreservation optionsHCT physiciansSurvival rateAvailable HLAEleven participantsInfertility
Clinical Trials
Current Trials
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
HIC ID2000037926RoleSub InvestigatorPrimary Completion Date04/28/2031Recruiting ParticipantsGenderBothAge5 years - 60 yearsA Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML
HIC ID2000034938RoleSub InvestigatorPrimary Completion Date02/01/2027Recruiting ParticipantsA Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
HIC ID2000032978RoleSub InvestigatorPrimary Completion Date12/30/2026Recruiting ParticipantsPediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
HIC ID2000034939RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsA Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
HIC ID2000032775RoleSub InvestigatorPrimary Completion Date03/31/2031Recruiting Participants
Clinical Care
Overview
Nitya Bakshi, MBBS (a medical degree awarded in countries outside the U.S.), specializes in pediatric hematology and oncology, focusing on the care of children and young adults with sickle cell disease.
"Sickle cell disease is a blood disorder that is inherited," explains Dr. Bakshi. It primarily affects individuals of African descent and is characterized by the production of abnormal hemoglobin, which can cause red blood cells to become rigid and shaped like a sickle. This can lead to blockages in blood flow and result in chronic pain, anemia, and other complications.
Dr. Bakshi emphasizes personalized pain management strategies for patients with sickle cell disease, aiming to reduce pain and enhance overall health. “The goal of treatment is to have as healthy a life as possible,” she says.
As an associate professor of pediatrics at Yale School of Medicine, Dr. Bakshi's research focuses on understanding chronic pain in sickle cell disease.
Dr. Bakshi received her medical degree from Christian Medical College in India and completed a master's degree at the University of Pittsburgh.
Clinical Specialties
Pediatric Hematology & Oncology
Fact Sheets
Sickle Cell Disease
Learn More on Yale MedicineChronic Pain
Learn More on Yale MedicineChronic Pelvic Pain in Women
Learn More on Yale MedicineChronic Stress
Learn More on Yale Medicine
Yale Medicine News
News
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.